Associate Professor of Oncology, Mayo Clinic Cancer Center, Mayo Clinic Florida
Hematology
Dr. James M. Foran, MD
|
|
Give Review
Dr. James M. Foran is an expert in the field of Hematology. He received awards:"Regional Top Doctor". James Foran is also published. He has 48 publications published. The lastest publication: "High-dose therapy with autologous haematopoietic support in patients with transformed follicular lymphoma: a study of 27 patients from a single centre.' James Foran accepts all Medicare patients.
Publications
- Impact of access to NCI- and NCCN-designated Cancer centers on outcomes for multiple myeloma patients: A SEER registry analysis.
- Disseminated extranodal marginal zone Lymphoma involving the gastrocnemius muscle with sural neuroLymphomatosis.
- Etiologic Heterogeneity Among Non-Hodgkin Lymphoma Subtypes: The InterLymph Non-Hodgkin Lymphoma Subtypes Project.
- Frontline Therapy of AML: Should the Older Patient be Treated Differently?
- Socioeconomic disparities in mortality after diffuse large B-cell Lymphoma in the modern treatment era.
- The investigational agent MLN2238 induces apoptosis and is cytotoxic to CLL Cells in vitro, as a single agent and in combination with other drugs.
- Rituximab use and survival after diffuse large B-cell or follicular Lymphoma: a population-based study.
- Unrelated donor allogeneic transplantation after failure of autologous transplantation for Acute myeloid leukemia: a study from the cibmtr.
- Examining racial differences in diffuse large B-cell Lymphoma presentation and survival.
- Safety and Clinical Activity of a Combination Therapy Comprising Two Antibody-Based Targeting Agents for the Treatment of Non-Hodgkin Lymphoma: Results of a Phase I/II...
- A Case of Acute Promyelocytic Leukemia Without RAR? Rearrangement and Apparently Normal Cytogenetics.
- Acute myeloid leukemia.
- NCCN Clinical Practice Guidelines in Oncology: Myelodysplastic syndromes.
- An examination of educational gaps in the diagnosis and treatment of Myelodysplastic syndromes.
- Hepatitis C in the rituximab era.
- NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: report from the Committ...
- New prognostic markers in Acute myeloid leukemia: perspective from the clinic.
- Improvements in survival after follicular Lymphoma by race/ethnicity and socioeconomic status: a population-based study.
- Successful treatment of T-cell prolymphocytic Leukemia with full-intensity conditioning followed by matched unrelated donor allogeneic stem cell transplantation.
- An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in Acute myeloid leukemia patients.
- Lymphodepleting effects and safety of pentostatin for nonmyeloablative allogeneic stem-Cell transplantation.
- Myelodysplastic syndromes.
- Antibody-based therapy of non-Hodgkin''s Lymphoma.
- Immunological and clinical effects of post-transplant G-CSF versus placebo in T-Cell replete allogeneic blood transplant patients: results from a randomized double-bli...
- Myeloid growth factors. Clinical practice guidelines in oncology.
- Myositis, polyserositis with a large pericardial effusion and constrictive pericarditis as manifestations of Chronic graft-versus-host disease after non-myeloablative ...
- Myeloid growth factors clinical practice guidelines in oncology.
- Myelodysplastic syndromes clinical practice guidelines in oncology.
- Acute myeloid leukemia clinical practice guidelines in oncology.
- Pharmacokinetic study of single doses of oral fludarabine phosphate in patients with "low-grade" non-Hodgkin's lymphoma and B-cell chronic lymphocytic Leukemia.
- European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell Lymphoma and previously treated mantle-cell...
- Peripheral T-cell Lymphoma following rituximab therapy for B-cell Lymphoma.
- Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's Lymphoma: resul...
- Therapy-related myelodysplasia and secondary Acute myelogenous leukemia after high-dose therapy with autologous hematopoietic progenitor-cell support for lymphoid mali...
- Patterns of outcome following recurrence after myeloablative therapy with autologous bone marrow transplantation for follicular Lymphoma.
- Low-dose continuous chemotherapy (LBCMVD-56) for refractory and relapsing Lymphoma.
- Interphase fluorescence in situ hybridization studies for the detection of 9q34 deletions in chronic myelogenous Leukemia: a practical approach to clinical diagnosis.
- High-dose therapy with autologous haematopoietic support in patients with transformed follicular Lymphoma: a study of 27 patients from a single centre.
- A UK multicentre phase II study of rituximab (chimaeric anti-CD20 monoclonal antibody) in patients with follicular Lymphoma, with PCR monitoring of molecular response.
- A phase II study to evaluate the combination of fludarabine, mitoxantrone and dexamethasone (FMD) in patients with follicular Lymphoma.
- Factors which predict unsuccessful mobilisation of peripheral blood progenitor cells following G-CSF alone in patients with non-Hodgkin''s Lymphoma.
- Multicenter phase II study of fludarabine phosphate for patients with newly diagnosed lymphoplasmacytoid Lymphoma, Waldenström's macroglobulinemia, and mantle-cell lym...
- A phase II protection study of BB-10010 in patients with high grade non-Hodgkin''s Lymphoma undergoing intensive chemotherapy.
- Reversible posterior leukoencephalopathy syndrome following CHOP chemotherapy for diffuse large B-cell Lymphoma.
- Immunocytoma: a retrospective analysis from St Bartholomew's Hospital-1972 to 1996.
- Treatment of mantle-cell Lymphoma with Rituximab (chimeric monoclonal anti-CD20 antibody): analysis of factors associated with response.
- The Hedgehog pathway as targetable vulnerability with 5-azacytidine in myelodysplastic syndrome and Acute myeloid leukemia.
Procedures Preformed
- HPC Transplantation (Stem Cell Transplant)
- Plasmapheresis
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Anemia
- Bile Duct Cancer
- Bladder Cancer
- View All
Doctors Specialties
- Medical Oncology
- Oncology
- Hematology
Accepted Insurances
Awards
- Regional Top Doctor
Education
-
Brigham and Women's Hospital -
Beth Israel Deaconess Medical Center -
University of Manitoba
Hospital
-
Mayo Clinic - Jacksonville, Florida
Drug Facts
| NPI NUMBER | 1992749139 | |
| NPPES Provider LastName | FORAN | |
| NPPES Provider FirstName | JAMES | |
| NPPES Provider ZIPCode | 322241865 | |
| NPPES Provider State | FL | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 399.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1992749139 |
| Last Name Of The Provider | FORAN |
| First Name Of The Provider | JAMES |
| View All |
Similar Doctors
|
|
Dr. Pooja P. Advani, MD
 This Doctor is OpenDoctor Recommended.
|
|
Dr. Daniele J. Montgomery, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Sahana R. Kalmadi, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Steven D. Siegel, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jason S. Starr, DO |
|
|
Dr. Kenneth H. Goldstein, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sheryl D. Michels, MD |
|
Dr. Sejal S. Kuthiala, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jeffrey M. Harris, MD |
|
|
Dr. Jason D. Hew, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Fauzia N. Rana, MD |
|
|
Dr. David G. Hedrick, MD |